Comparative Pharmacology
Head-to-head clinical analysis: ARAMINE versus DROXIDOPA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARAMINE versus DROXIDOPA.
ARAMINE vs DROXIDOPA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Direct-acting sympathomimetic amine that stimulates alpha-adrenergic receptors, causing vasoconstriction and increased blood pressure.
Droxidopa is a synthetic precursor of norepinephrine that increases norepinephrine levels in the peripheral nervous system, thereby improving sympathetic tone and blood pressure regulation.
Intravenous infusion: 1-10 mg initially, then 0.5-5 mg/hr titrated to blood pressure. Intramuscular or subcutaneous: 2-10 mg every 2 hours as needed.
100-200 mg orally three times daily, with a maximum of 600 mg three times daily if needed.
None Documented
None Documented
Terminal elimination half-life is 2-4 hours. Clinical context: Requires continuous infusion for sustained blood pressure support.
Clinical Note
moderateDroxidopa + Torasemide
"Droxidopa may increase the hypokalemic activities of Torasemide."
Clinical Note
moderateDroxidopa + Etacrynic acid
"Droxidopa may increase the hypokalemic activities of Etacrynic acid."
Clinical Note
moderateDroxidopa + Furosemide
"Droxidopa may increase the hypokalemic activities of Furosemide."
Clinical Note
moderateDroxidopa + Bumetanide
"Droxidopa may increase the hypokalemic activities of Bumetanide."
2–3 hours; terminal half-life approximately 2.5 hours, requiring 3–4 times daily dosing to maintain plasma levels.
Primarily renal: 85% unchanged drug in urine within 24 hours. Biliary/fecal: <5%.
Renal: ~75% as unchanged drug and metabolites (including 3-O-methyldroxidopa and other conjugates); biliary/fecal: minimal (<5%).
Category C
Category C
Vasopressor
Vasopressor